Alterity Therapeutics Limited, a biotechnology company operating within the health care sector, has been steadfast in its mission to develop therapeutic drugs aimed at treating Alzheimer’s diseases and age-related disorders. Based in Melbourne, Australia, the company has carved a niche for itself by focusing on innovative research and development in the realm of neurodegenerative diseases. As of 3 March 2026, Alterity Therapeutics remains listed on the ASX All Markets stock exchange, with its shares trading at AUD 0.008.
Despite the absence of new headlines as of the latest update, the company’s recent activities have not gone unnoticed. On 2 March 2026, Alterity Therapeutics issued a press release acknowledging Multiple System Atrophy Awareness Month. This initiative underscores the company’s commitment to raising awareness about the urgent need for disease-modifying therapies, reflecting its broader mission to address unmet medical needs in neurodegenerative diseases.
Financially, Alterity Therapeutics has experienced fluctuations in its stock price over the past year. The company’s shares reached a 52-week high of AUD 0.0175 on 27 July 2025, demonstrating investor confidence at that time. However, the stock has since declined to its current price, which remains above the 52-week low of AUD 0.006 recorded on 6 April 2025. This volatility is reflected in the company’s price-to-earnings ratio of -4.21, indicating negative earnings. Despite this, the price-to-book ratio of 2.05182 suggests that the market values the company at more than double its book value, highlighting investor optimism about its future prospects.
With a market capitalization of AUD 87,003,336, Alterity Therapeutics continues to focus on its core mission of providing care for patients in Australia. The company’s dedication to advancing therapeutic solutions for Alzheimer’s and age-related disorders remains a cornerstone of its operations. For those interested in learning more about Alterity Therapeutics’ activities and developments, further information is available on their website at www.alteritytherapeutics.com .
As the company navigates the challenges and opportunities within the biotechnology sector, its commitment to innovation and patient care remains unwavering. Alterity Therapeutics’ efforts to raise awareness and develop new therapies for neurodegenerative diseases continue to position it as a key player in the health care industry.
